



MOLECULAR TEMPLATES

### Company Overview

Molecular Templates is focused on the discovery, development, and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.

### Molecular Templates Announces FDA Acceptance of IND Application for MT-6402, a PD-L1-Targeted Engineered Toxin Body Enabled with Proprietary Antigen Seeding Technology

Jan 19 2021, 8:00 AM EST

### Molecular Templates, Inc. Provides Update on MT-5111 Phase 1 Study

Dec 21 2020, 4:30 PM EST

### Molecular Templates to Participate in Upcoming Virtual Investor Conferences

Nov 16 2020, 4:30 PM EST

### Stock Overview

Symbol	MTEM
Exchange	Nasdaq
Market Cap	589.08m
Last Price	\$11.79
52-Week Range	\$7.52 - \$19.13

01/19/2021 04:00 PM EST

### Investor Relations

Adam Cutler  
Chief Financial Officer  
T: 862-204-4006  
[adam.cutler@mtem.com](mailto:adam.cutler@mtem.com)

### Management Team

#### Eric Poma, Ph.D.

Chief Executive Officer & Chief Scientific Officer

#### Jason Kim

President & Chief Operating Officer

#### Roger Waltzman, M.D.

Chief Medical Officer

#### Adam Cutler

Chief Financial Officer

#### Jack Higgins, Ph.D.

Chief Development Sciences Officer

#### Betty Chang, Ph.D.

Senior Vice President, Translational Research and Early Development

#### Michael Dowd

Senior Vice President, Project & Alliance Management

#### Megan Filoon

Corporate Counsel

#### Ryan Hawkins

Senior Vice President and Head of Manufacturing

#### Dennis Jones

Senior Vice President, Quality

#### Sean McLennan

Senior Vice President, Finance and Corporate Controller

#### Joseph Phillips, Ph.D.

Senior Vice President and Head of CMC Development

#### Kristen Quigley

Senior Vice President, Clinical Operations

### Molecular Templates, Inc.

9301 Amberglen Blvd  
Suite 100  
Austin, TX 78729

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the

property of their respective companies.